A Randomized, Controlled, Open, Multicenter, Phase II/III Clinical Study to Evaluate the Safety and Efficacy of Vebreltinib Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN)

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 01 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vebreltinib (Primary) ; Cisplatin; Etoposide; Temozolomide
Indications Astrocytoma; Glioblastoma
Focus Therapeutic Use
Acronyms FUGEN Study
Sponsors Beijing Pearl Biotechnology

Most Recent Events

04 Jun 2024 Results(n=42) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
04 Jun 2024 Results presented in the Apollomics Media Release.
04 Jun 2024 According to an Apollomics media release, data from the study were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight